KRAS testing in clinical laboratory: optimizing targeted therapy.

Abstract excerpt

BACKGROUND/AIM: Activating mutations in the KRAS gene are found in more than 30% of colorectal tumors, where they are associated with a poor response to anti-epidermal growth factor receptor therapies. Mutation testing techniques have therefore become an urgent concern. Several methods for KRAS mutation detection have been described in the literature. Most of these are laboratory developed tests and only a few...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biopsy, Fine-Needle
• Share to DNA, Neoplasm
• Share to Pancreatic Neoplasms